Biohaven (BHVN) Stock Price, News & Analysis

Company Overview

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders.

In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access.

Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.

Key Stats

• Today's Range: $8.43 to $8.84
• 50-Day Range: $8.10 to $11.00
• 52-Week Range: $7.48 to $18.57
• Volume: 2.11 million shs
• Average Volume: 1.85 million shs
• Market Capitalization: $1.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.27
• Consensus Rating: Moderate Buy

Biohaven Stock Analysis - MarketRank™

Biohaven scored higher than 45% of companies evaluated by MarketBeat, and ranked 583rd out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 2 strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Biohaven has a consensus price target of $22.27, representing about 162.1% upside from its current price of $8.50.

Amount of Analyst Coverage

Biohaven has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biohaven are expected to grow in the coming year, from ($2.97) to ($2.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biohaven is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biohaven is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biohaven has a P/B Ratio of 21.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.16% of the float of Biohaven has been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 14.37, which indicates bearish sentiment.

Change versus previous month

Short interest in Biohaven has recently increased by 4.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biohaven does not currently pay a dividend.

Dividend Growth

Biohaven does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Biohaven has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biohaven this week, compared to 9 articles on an average week.

Search Interest

Only 7 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biohaven insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHVN
• Previous Symbol: NASDAQ:BHVN
• CIK: 1935979
• Web: www.biohavenpharma.com
• Phone: 203-404-0410
• Fax: N/A
• Employees: 239
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Biohaven: $22.27
• High Price Target: $75.00
• Low Price Target: $9.00
• Potential Upside/Downside: +162.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$738.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -866.46%
• Return on Assets: -137.99%

Debt

• Debt-to-Equity Ratio: 1.87
• Current Ratio: 7.41
• Quick Ratio: 7.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 21.78

Miscellaneous

• Outstanding Shares: 150,560,000
• Free Float: 129,784,000
• Market Cap: $1.28 billion
• Optionable: Optionable
• Beta: 1.32